Fidelity Investments
TTNP

Fidelity Investments’s Titan Pharmaceuticals TTNP Stock Holding History

Fidelity Investments’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$5 – 5733
2024
Q2 		$5 Buy
+1
New +$7 ﹤0.01% 5317
2023
Q4 		– Sell
-3
Closed -$29 – 5656
2023
Q3 		$29 Hold
3
– – ﹤0.01% 5027
2023
Q2 		$40 Sell
3
-1
-25% -$15 ﹤0.01% 5056
2023
Q1 		$58 Sell
4
-13
-76% -$233 ﹤0.01% 4959
2022
Q4 		$268 Buy
+17
New +$321 ﹤0.01% 4796
2022
Q3 		– Hold
0
– – – 5411
2022
Q2 		– Hold
0
– – – 5488
2022
Q1 		– Hold
0
– – – 5486
2021
Q4 		– Hold
0
– – – 4931
2021
Q3 		– Hold
0
– – – 5033
2021
Q2 		– Hold
0
– – – 4879
2019
Q4 		– Hold
0
– – – 4267
2019
Q3 		– Hold
0
– – – 4231

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Fidelity Investments's TTNP Position: Q3 2024 in Review

Fidelity Investments sold out of Titan Pharmaceuticals (TTNP) in Q3 2024, closing a stake of 1 share — an estimated $5 sold.

Fidelity Investments first reported a position in TTNP in Q4 2022 and held it in 5 quarters. The position peaked at $268 in Q4 2022. 16 funds tracked by Wall St. Rank hold TTNP as of Q3 2024.

  • Fidelity Investments reported no remaining Titan Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fidelity Investments sold 1 Titan Pharmaceuticals share in Q3 2024, an estimated $5.
  • Fidelity Investments first reported a position in Titan Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Fidelity Investments's Titan Pharmaceuticals position peaked at $268 in Q4 2022.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.